肺腺癌组织p190-B RhoGAP蛋白表达及其与预后的相关性分析  

Expression and correlation with prognosis of p190-B RhoGAP in patients with lung adenocarcinoma

作　　者：王成[1] 李宝重[2] 万军庭[2] 谭小刚[2] 邱斌[2] 邢学忠[2] 邵康[2] 赫捷[2] 张有成[1] 

机构地区：[1]兰州大学第二医院胸外科,甘肃兰州730030 [2]中国协和医科大学中国医学科学院肿瘤医院肿瘤研究所胸外科,北京100021

出　　处：《中华肿瘤防治杂志》2009年第19期1486-1489,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨p190-B RhoGAP在肺腺癌组织中的表达及其临床和预后意义。方法:收集160例接受手术治疗的肺腺癌患者临床病理资料,应用免疫组化检测肺腺癌组织芯片中p190-B RhoGAP蛋白的表达,分析其与临床和预后的相关性。所有患者随访5年。结果:p190-B RhoGAP蛋白在43.75%(70/160)的肺腺癌组织中高表达(P=0.003),主要定位于癌细胞的胞质内,其表达水平与患者的临床病理分期(P=0.018)、组织分化(P=0.047)和预后(P=0.015)密切相关,是一个独立的预后因素。与p190-B RhoGAP蛋白表达阴性相比,表达阳性的肺腺癌患者预后差(5年生存率45.7%vs23.5%)。结论:p190-B RhoGAP可能是参与肺腺癌发生发展过程的相关基因之一。OBJECTIVE：To detect the expression of p190-B RhoGAP in lung adenocarcinoma and inverstigate its clinical significance. METHODS：The records of 160 patients undergoing complete resection for lung adenocarcinoma were reviewed to collect datas. The expression levels and associativity with clinicopathologic characteristics of p190-B RhoGAP were analyzed using immunohistochemistry method. Statistical analysis was performed to correlate its expression with clinical characteristics and prognosis. RESULTS：p190-B RhoGAP was shown to be over expressed in 43.75%（70/160） lung adenocarcinoma samples （P=0.003）,and mainly located in cytoplasm. The expression of p190-B RhoGAP was significantly correlated with the stage of clinicopathology （P=0.018）,histologic differentiation （P=0.047）,and prognosis （P=0.015）;it is a self-sustainingly prognosis factor. Compared with low expressed ones,the patiens with increased p190-B RhoGAP expression was associated with poor survival of lung adenocarcinoma （5-year survival rate：45.7% vs 23.5%）. CONCLUSION：p190-B RhoGAP may be a valuable tumor marker for lung adenocarcinoma.

关 键 词：肺肿瘤 腺癌 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]